UNLIMITED
Alcohol Use: Perhaps It Is for the Faint of Heart - Frankly Speaking EP 109: Credits: 0.25 AMA PRA Category 1 Credits™ Claim CME/CE credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-109-alcohol-hf Overview: In a recent study, data from the Cardiovascular Health Study examined the association between al... by Pri-Med Podcastsratings:
Length:
34 minutes
Released:
Mar 22, 2024
Format:
Podcast episode
Description
Credits: 0.50 AMA PRA Category 1 Credits™, 0.50 ABIM MOC or 0.56 AANP, including 0.56 AANP Pharm
CME/CE Information and Claim Credit: https://www.pri-med.com/online-cme-ce/podcast/practical-approaches-to-the-pharmacologic-treatment-of-obesity
Overview: In this podcast expert faculty will review the available options and discuss best practices for prescribing and monitoring long-term anti-obesity medications (AOM) as an important component of a chronic disease approach to obesity management. The discussion will include the indications, efficacy, safety, and adverse effects of currently FDA-approved AOM as well as the evidence supporting new agents like the GLP-1 receptor agonists and the newly approved dual GIP/GLP-1 receptor agonist tirzepatide.
CME/CE Information and Claim Credit: https://www.pri-med.com/online-cme-ce/podcast/practical-approaches-to-the-pharmacologic-treatment-of-obesity
Overview: In this podcast expert faculty will review the available options and discuss best practices for prescribing and monitoring long-term anti-obesity medications (AOM) as an important component of a chronic disease approach to obesity management. The discussion will include the indications, efficacy, safety, and adverse effects of currently FDA-approved AOM as well as the evidence supporting new agents like the GLP-1 receptor agonists and the newly approved dual GIP/GLP-1 receptor agonist tirzepatide.
Released:
Mar 22, 2024
Format:
Podcast episode
Titles in the series (100)
- 9 min listen